Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells

详细信息    查看全文

• 作者：Shinha Han (2)
  Kwanghee Kim (2)
  Youngcheon Song (2)
  Hyunyul Kim (2)
  Jeunghak Kwon (2)
  Young-Hee Lee (1)
  Chong-Kil Lee (1)
  Sang-Jin Lee (2)
  Namjoo Ha (2)
  Kyungjae Kim (2)
  
• 关键词：Auranofin ; Dendritic cells ; Cross ; presentation ; Immunosuppression ; MHC
• 刊名：Archives of Pharmacal Research
• 出版年：2008
• 出版时间：March 2008
• 年：2008
• 卷：31
• 期：3
• 页码：370-376
• 全文大小：335KB
• 参考文献：1. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., and Palucka, K., Immunobiology of dendritic cells. / Annu. Rev. Immunol., 18, 767鈥?11 (2000). CrossRef
  2. Berglof, F. E., Berglof, K., and Walz, D. T., Auranofin: an oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. / J. Rheumatol., 5, 68鈥?4 (1978).
  3. Bernhard, G. C., Auranofin therapy in rheumatoid arthritis. / J. Lab. Clin. Med., 100, 167鈥?77 (1982).
  4. Bevan. M. J., Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. / J. Exp. Med., 143, 1283鈥?288 (1976). CrossRef
  5. Blodgett, R. C., Heuer, M. A., and Pietrusko, R. G., Auranofin: a unique oral chrysotherapeutic agent. / Semin. Arthritis Rheum., 13, 255鈥?73 (1984). CrossRef
  6. Blondeson. J., The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. / Gen. Pharmacol., 29, 127鈥?50 (1997).
  7. Chefalo, P. J., Grandea, A. G., Kaer, L. V., and Harding, C. V., Tapasin-/-and TAP1-/-macrophages are deficient in vacuolar alternate class I MHC (MHC-I) processing due to decreased MHC-I stability at phagolysosomal pH. / J. Immunol., 170, 5825鈥?833 (2003).
  8. Cyong, J. and Otsuka, Y. A., A pharmacological study of the anti-inflammatory activity of / Chinese herbs. A review. Acupunct. / Electrother. Res., 7, 173鈥?02 (1982).
  9. Day, P. M., Esquivel, F., Lukszo, J., Bennink, R., and Yewdell, J. W., Effect of TAP on the generation and intracellular trafficking of peptide-receptive major histocompatibility complex class I molecules. / Immunity., 2, 137鈥?47 (1995). CrossRef
  10. Forestier, J., L鈥檃urotherapie dans les rhumatismes chro-niques. / Bull. Mem. Soc. Med. Hop. Paris., 53, 323鈥?28 (1929).
  11. Graninger, W., Seidl, G., Kovarik, J., Pinggera, W., and Smolen, J. S., Oral gold therapy in a patient with rheumatoid arthritis and preexisting uremia. / Arthritis Rheum., 28, 710鈥?12 (1985). CrossRef
  12. Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C., and Amigorena, S., Antigen presentation and T cell stimulation by dendritic cells. / Annu. Rev. Immunol., 20, 621鈥?67 (2002). CrossRef
  13. Harding, C. V., Phagocytic processing of antigens for presentation by MHC molecules. / Trend. Cell. Biol., 5, 105鈥?09 (1995). CrossRef
  14. Harding, C. V., Collins, D. S., Kanagawa, O., and Unanue, E. R., Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. / J. Immunol., 147, 2860鈥?863 (1991).
  15. Haringman, J. J. and Tak, P. P., Chemokine blockade: a new era in the treatment of rheumatoid arthritis? / Arthritis Res. Ther., 6, 93鈥?7 (2004). CrossRef
  16. Ho, L. J. and Lai, J. H., Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders. / Curr. Drug Metab., 5, 181鈥?92 (2004). CrossRef
  17. Hunt, L. B., The Figuiers of Montpellier. / J. Soc. Study Alch. & Early Chem., 26, 221鈥?23 (1979).
  18. Karttunen, J., Sanderson, S., and Shastri, N., Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. / Proc. Natl. Acad. Sci., 89, 6020鈥?024 (1992). CrossRef
  19. Kean, W. F., Hart, L., and Buchanan, W. W., Auranofin. / Br. J. Rheumatol., 36, 560鈥?72 (1997). CrossRef
  20. Kean, W. F., Kassam, Y. B., and Lock, C. J. L. / et al., Antithrombin activity of gold sodium thiomalate. / Clin. Pharmacol. Ther., 35, 627鈥?32 (1984).
  21. Lee, Y. R., Yang, I. H., Lee, Y. H., Im, S. A., Song, S., Li, H., Han, K., Kim, K., Eo, S. K., and Lee, C. K., Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. / Blood., 105, 3951鈥?955 (2005). CrossRef
  22. Liu, J., Akahoshi, T., Matsui, T., and Kondo, H., Effect of auranofin, an antirheumatic drug, on neutrophil apoptosis. / Inflamm. Res., 49, 445鈥?51 (2000). CrossRef
  23. Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R., and Germain, R. N., Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. / Immunity, 6, 715鈥?26. (1997). CrossRef
  24. Shen, Z., Reznikoff, G., Dranoff, G., and Rock K. L., Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. / J. Immunol., 158, 2723鈥?730 (1997).
  25. Simon, L. S., DMARDs in the treatment of rheumatoid arthritis: current agents and future developments. / Int. J. Clin. Pract., 54, 243鈥?49 (2000).
  26. Walz, E.T., Dimartino, M. J., Griswold, D. E., Intoccia, A. P., and Flanagan, T. L., Biologic actions and pharmacokinetic studies of anofin. / Am. J. Med., 75, 90鈥?08 (1983). CrossRef
  
• 作者单位：Shinha Han (2)
  Kwanghee Kim (2)
  Youngcheon Song (2)
  Hyunyul Kim (2)
  Jeunghak Kwon (2)
  Young-Hee Lee (1)
  Chong-Kil Lee (1)
  Sang-Jin Lee (2)
  Namjoo Ha (2)
  Kyungjae Kim (2)
  
  2. Department of Pharmacy, Sahmyook University, Seoul, 139-742, Korea
  1. College of Pharmacy, Chungbuk National University, Cheongju, 360-763, Korea
  
• ISSN：1976-3786

文摘

Auranofin (AF), an orally administered, gold-based, anti-arthritic agent, has emerged as a clinically useful therapeutic drug for the treatment of rheumatoid arthritis. In the present study, we examined the effects of AF on major histocompatibility complex (MHC)-restricted antigen presentation in dendritic cells (DCs), which are the most important accessory cells for the induction of T cell responses. A mouse dendritic cell line, DC2.4 cells, and DCs that were generated from mouse bone marrow cells by culturing with granulocyte macrophage-colony stimulating factor (GM-CSF) and interleukin (IL)-4 were each pretreated with AF for 2 hr, and then incubated with ovalbumin (OVA). After the 2-hr incubation, the DCs were fixed, and the amounts of OVA peptide-H-2Kb complexes were assessed using OVa-specific CD8+ T cells. AF inhibited MHC class I-restricted presentation of exogenous OVA. This inhibitory activity of AF appeared to be due not only to the inhibition of the phagocytic activity of DCs, but also to the suppression of MHC molecule expression on DCs. AF also inhibited MHC class II-restricted presentation of exogenous OVA. These results show that AF exerts immunosuppressive activity at least in part by inhibiting MHC-restricted antigen presentation in professional antigen-presenting cells.